Key facts
- This page summarizes Chris Freeman's Form 4 filing for Guardant Health, Inc. (GH).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Jun 2024, 18:40.
Chris Freeman - 15 Jun 2024 Form 4 Insider Report for Guardant Health, Inc. (GH)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- GH
- Reported as of
- 15 Jun 2024
- Net transaction value
- -$86,703
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2024, 18:40:10 UTC
- Prior SEC filing
- 02 Apr 2024
- Next SEC filing
- 02 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ John G. Saia, as attorney-in-fact for Chris Freeman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Chris Freeman filed Form 4 for Guardant Health, Inc. (GH) on 17 Jun 2024.
Change
- Previous filing in this sequence was filed on 02 Apr 2024.
- Current net transaction value: -$86,703.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GH
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +4,879
- Change %
- +29%
- Price
- $0.000000
- Shares after
- 21,946
- Date
- 15 Jun 2024
- Ownership
- Direct
GH
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +5,523
- Change %
- +25%
- Price
- $0.000000
- Shares after
- 27,469
- Date
- 15 Jun 2024
- Ownership
- Direct
GH
transaction
Common Stock
Tax liability
- Transaction value
- $86,703
- Shares
- -2,870
- Change %
- -10%
- Price
- $30.21
- Shares after
- 24,599
- Date
- 15 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GH
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -4,879
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 4,879
- Date
- 15 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,879
- Exercise price
- $0.000000
- Footnotes
- F2, F3
GH
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -5,523
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 11,215
- Date
- 15 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,523
- Exercise price
- $0.000000
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
Footnote F2
The restricted stock unit vests as to 25% of the shares subject to such award on June 15, 2022, and as to the remaining 75% of the shares subject to such award in substantially equal installments on each anniversary of June 15, 2022, during the three-year period thereafter.
Footnote F3
Not applicable to Restricted Stock Units
Footnote F4
This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vests on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Footnote F5
Not applicable for Restricted Stock Units.
SEC remarks
Table I includes 1,096 shares acquired under Guardant Health's Employee Stock Purchase Plan on 5/14/2024.